The top medtech trends of 2023 included innovations such as artificial intelligence, new GLP-1 weight loss drugs and some long-awaited medtech finally receiving regulatory nods. With health providers facing additional challenges on top of an ever-uncertain economic environment, medtech companies also made major readjustments: layoffs, spinoffs, reorganizations and much more. Here are the top stories […]
ReCor Medical
What’s next for Medtronic’s RDN program after FDA approval?
Medtronic is planning its first commercial renal denervation (RDN) cases and is already running a postmarket study after winning FDA approval of its Symplicity Spyral system for hypertension. In an interview before the Thanksgiving break, Medtronic SVP Jason Weidman — who’s also president of the company’s coronary and RDN business — said he expects the […]
Recor Medical launches renal denervation system, announces first commercial cases
Recor Medical announced the first commercial uses of its Paradise ultrasound renal denervation (uRDN) system for treating hypertension. The first commercial uses follow the company’s landmark FDA approval for Paradise last week. Approval allows for the use of Paradise as an adjunctive treatment option when lifestyle changes and medications fail to control a patient’s blood […]
Recor Medical wins first FDA nod for renal denervation to treat hypertension
Recor Medical announced that the FDA approved its Paradise ultrasound renal denervation (RDN) system for treating hypertension. The long-awaited approval for the Otsuka Medical Devices portfolio company allows for the use of Paradise as an adjunctive treatment option when lifestyle changes and medications fail to adequately control a patient’s blood pressure. Paradise had looked the […]
Recor Medical presents more data supporting its renal denervation system
Otsuka Medical Devices’ Recor Medical announced another set of positive study results for its Paradise ultrasound renal denervation (uRDN) system. A combined analysis of six-month follow-up data from three RADIANCE global studies evaluated Paradise as a hypertension treatment. The analysis demonstrated maintained blood pressure (BP) reduction following treatment with uRDN compared to sham. It also […]
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE […]
ReCor Medical wins FDA panel nod for its renal denervation system
ReCor Medical announced that an FDA panel has voted in favor of the safety and efficacy of its Paradise ultrasound renal denervation (RDN) system for treating hypertension. On Aug. 22, the Circulatory Systems Devices Panel of the FDA’s Medical Devices Advisory Committee voted 12–0 in favor with regard to safety and 8–3 in favor, with […]
FDA review panel: Medtronic Symplicity Spyral RDN risks outweigh benefits
An FDA review panel voted against recommending approval of Medtronic’s Symplicity Spyral renal denervation (RDN) therapy for hypertension under the proposed indications. The panel unanimously said the minimally invasive catheter system is safe, but was nearly split on efficacy. With six members voting that the benefits outweighed the risk, six voting the other way and […]
ReCor Medical is pleased with updated renal denervation guidelines in Europe
ReCor Medical today applauded updated and expanded recommendations for managing arterial hypertension overseas. The European Hypertension Society (ESH) this month issued updated guidelines on the role of renal denervation in the hypertension care pathway. It announced the guidelines at the ESH 32nd Annual Meeting and simultaneously published them in the Journal of Hypertension. These new guidelines serve […]
ReCor Medical announces more positive study results for its renal denervation system
ReCor Medical announced today that its Paradise ultrasound renal denervation (uRDN) system successfully reduced blood pressure in a study. Palo Alto, California-based ReCor published primary endpoint results from its Radiance II trial in the Journal of the American Medical Association (JAMA). Results showed success for Paradise in reducing blood pressure compared to sham. Additionally, pooled analysis […]
ReCor Medical names Siemens Healthineers, Terumo veteran as CEO
ReCor Medical today announced it appointed Lara Barghout as president and CEO. Barghout will succeed Andrew Weiss. She will lead the Palo Alto, California-based company’s business strategy and organization in a new direction, according to the company. The goal is to commercialize ReCor’s Paradise ultrasound renal denervation (uRDN) system that treats hypertension. “I am honored […]